- BioMark Diagnostics (BUX) is participating in a research project that aims to enhance the efficiency of lung cancer screening programs
- Researchers from BioMark Diagnostic Solutions will work with pharmaceutical companies AstraZeneca and Pfizer Canada
- The new screening tools will combine various biomarkers and integrated using AI
- BioMark is a Canadian diagnostic oncology-focused company developing proprietary, non-invasive, and accurate liquid biopsy-based cancer diagnostic solutions
- Shares in BioMark Diagnostics Inc. (BUX) are up 9.62 per cent, trading at $0.285 per share
BioMark Diagnostics (BUX) will participate in a research project that aims to enhance the efficiency of lung cancer screening programs.
This initiative, entitled “Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population,” is being led by Dr. Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (IUCPQ-UL).
Researchers from BioMark Diagnostic Solutions will work with pharmaceutical companies AstraZeneca and Pfizer Canada using data and samples from IUCPQ-UL’s biobank.
The new screening tools will combine radiomics, genetics, and metabolomics biomarkers which will be integrated using artificial intelligence.
The research will need about $3.5 million in funding and is sponsored in part by the Ministère de l’Économie et de l’Innovation (MEI) and a donation from Mr. Normand Lord to the IUCPQ Foundation.
“This is an important project for BioMark Diagnostic Solutions as we continue to develop our liquid biopsy assay for the early diagnosis of lung cancer to help at-risk Quebecers get access to an accurate detection test,” said BioMark’s general manager and Chief Scientific Officer.
Rashid Ahmed Bux, BioMark CEO, also commented on the project.
“BioMark is thrilled to be involved in this project,” he said, “and we wish to thank CQDM, MEI, IUCPQ Foundation, Astra Zeneca and Pfizer Canada for the financial and the clinical collaboration as we collectively aspire to develop better screening programs for early detection of lung cancer and thus improve patient’s journey globally.”
CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs.
BioMark is a Canadian diagnostic oncology-focused company developing proprietary, non-invasive, and accurate liquid biopsy-based cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively.
Shares in BioMark Diagnostics Inc. (BUX) are up 9.62 per cent, trading at $0.285 per share as of 3:28 pm EST.